OPEN ACCESS Freely available online

Mycobacterial Diseases

ISSN: 2161-1068

Commentary

Investigate Antimicrobial Agents to Prevent Tuberculosis

Varro Terentius*

Department of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou, China

DESCRIPTION

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, remains a global health threat, with millions affected annually. The emergence of drug-resistant strains underscores the urgency for effective anti-mycobacterial agents. This article explores the diverse arsenal of drugs combating TB, illuminate on their mechanisms, challenges, and future prospects.

First-line agents like rifampicin, isoniazid, ethambutol, and pyrazinamide

Rifampicin inhibits RNA polymerase, curtailing bacterial RNA synthesis. Isoniazid disrupts mycolic acid biosynthesis, important for cell wall integrity. Ethambutol targets arabinosyl transferase, impeding cell wall formation. Pyrazinamide's precise mechanism remains elusive but involves disrupting membrane transport and reducing pH within the bacteria.

Challenges with first-line agents

While effective, first-line agents face challenges. Rifampicin resistance often arises due to mutations in the RNA polymerase gene. Isoniazid resistance can stem from mutations in *kat*G or *inh*A genes. Ethambutol resistance typically arises from mutations in the *embB* gene. Moreover, Pyrazinamide's efficacy varies with pH, posing challenges in acidic environments like phagosomes.

Second-line agents like streptomycin, fluoroquinolones, and aminoglycosides

Streptomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Fluoroquinolones like moxifloxacin target DNA gyrase, impeding DNA replication. Aminoglycosides like amikacin disrupt protein synthesis by binding to the 30S ribosomal subunit.

Challenges with second-line agents

Resistance to second-line agents is a growing concern. Streptomycin resistance often emerges due to mutations in the rpsL or rrs gene. Fluoroquinolone resistance can arise from mutations in DNA gyrase or efflux pump mechanisms. Aminoglycoside resistance stems from various mechanisms, including enzymatic inactivation and target site modification.

Novel approaches and adjunct therapies

Combating TB demands innovative strategies. Bedaquiline, inhibiting ATP synthase, offers hope against multidrug-resistant TB. Delamanid disrupts mycolic acid synthesis, showing efficacy against drug-resistant strains. Host-directed therapies, like vitamin D supplementation, bolster immune responses against TB.

Challenges in drug development

Developing new anti-mycobacterial agents faces hurdles. Drug-resistant TB strains necessitate novel targets and mechanisms. Balancing efficacy with safety profiles is important. Moreover, ensuring affordability and accessibility is vital, particularly in resource-limited settings. Addressing these challenges requires robust investment in research and development, alongside international collaboration to expedite the discovery and validation of novel therapeutics. Additionally, advocacy for equitable distribution and affordability is crucial for widespread access to these life-saving interventions.

Future perspectives

Advancements in genomics and computational biology offer insights into TB pathogenesis and drug resistance mechanisms. Targeted drug delivery systems enhance drug efficacy while minimizing side effects. Collaboration between researchers, pharmaceutical companies, and policymakers is imperative to tackle TB comprehensively. These scientific strides pave the way for personalized treatment regimens tailored to individual patients, optimizing therapeutic outcomes. Moreover, regulatory support and global funding are vital for translating research findings into accessible interventions, fostering a united front against tuberculosis.

CONCLUSION

Anti-mycobacterial agents form the basis of TB treatment, yet challenges persist amidst the emergence of drug-resistant

Correspondence to: Varro Terentius, Department of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou, China, E-mail: terevaro@edu.uk

Received: 01-Jan-2024, Manuscript No. MDTL-24-29578; **Editor assigned:** 03-Jan-2024, Pre QC No. MDTL-24-29578 (PQ); **Reviewed:** 17-Jan-2024, QC No. MDTL-24-29578; **Revised:** 24-Jan-2024, Manuscript No. MDTL-24-29578 (R); **Published:** 31-Jan-2024, DOI: 10.35248/2161-1068.24.14.419

Citation: Terentius V (2024) Investigate Antimicrobial Agents to Prevent Tuberculosis. Mycobact Dis. 14:419.

strains. Novel agents and adjunct therapies offer hope, but concerted efforts are required to overcome barriers in drug development and ensure equitable access to effective treatments. With continued research and collaboration, the vision of a TB-free world might eventually come to fruition.Through rigorous research and development, these agents offer hope in reducing tuberculosis incidence rates and curbing its transmission. Continued investigation into their efficacy and safety holds the potential to significantly contribute to the ongoing efforts to control and eventually eradicate tuberculosis on a global scale.